Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine

Area of Science:

• Virology
• Vaccinology
• Structural Biology

Background:

• Coxsackievirus B (CVB) are significant pathogens linked to myocarditis, cardiomyopathy, meningitis, and type 1 diabetes.
• Current enterovirus vaccines rely on traditional inactivated or live attenuated approaches.
• Virus-like particles (VLPs) offer advantages in manufacturing and epitope engineering for vaccine development.

Purpose of the Study:

• To describe the production of Coxsackievirus B3 virus-like particles (CVB3-VLPs) with improved yield and purity.
• To characterize the structure of CVB3-VLPs using Cryo-Electron Microscopy.
• To assess the immunogenicity of CVB3-VLPs in a mouse model.

Main Methods:

• Enhanced purification of CVB3-VLPs using tangential flow filtration and ion exchange chromatography.
• Cryo-Electron Microscopy imaging and single particle reconstruction to determine VLP structure.
• Immunization of C57BL/6J mice with non-adjuvanted CVB3-VLP vaccine and subsequent antibody level analysis.

Main Results:

• An improved purification method significantly increased CVB3-VLP production yield and purity, suitable for industrial scale.
• Cryo-Electron Microscopy revealed the average CVB3-VLP diameter to be 30.9 nm, larger than mature virions.
• Immunization induced high levels of neutralizing and total IgG antibodies, with a Th2 (IgG1) phenotype.

Conclusions:

• The optimized methodology enables efficient production of highly pure CVB3-VLPs.
• The structural data and immunogenicity findings support the potential of CVB3-VLPs as effective vaccine candidates.
• This approach could be valuable for developing future enterovirus VLP-based vaccines.